---
source_path: R2504J-PDF-ENG.md
pages: n/a-n/a
chunk_id: 143dab7da48148a5e291b53237ef32e84ea0873e
title: R2504J-PDF-ENG
---
## Two years earlier, by contrast, on December 12, the pharmaceutical

ﬁrm the Medicines Company had announced that it was going to buy

the specialty drugmaker Incline Therapeutics. It turned out to be very

similar to the Spansion deal in terms of value creation: A year later

the combined entity’s market cap was also 13% higher. But when Clive

Meanwell, the CEO of Medicines, had presented the deal to the ﬁnancial

markets, the response was lukewarm: The share price rose by only 1.8%.

Clearly, investors hadn’t understood the reasons for the purchase.

This turns out to be a pattern. When we analyzed a sample of 654

large deals in the United States that had taken place from 2012 to 2017,

we frequently found this kind of disparity between comparable deals.

With any given acquisition or merger, the markets might or might not

immediately factor in the value that the company predicted it would
